MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
6.17
-0.18
-2.83%
Opening 15:41 07/15 EDT
OPEN
6.39
PREV CLOSE
6.35
HIGH
6.43
LOW
6.08
VOLUME
616.39K
TURNOVER
--
52 WEEK HIGH
23.48
52 WEEK LOW
5.41
MARKET CAP
534.17M
P/E (TTM)
-2.9522
1D
5D
1M
3M
1Y
5Y
1D
Health Check: How Prudently Does Kura Oncology (NASDAQ:KURA) Use Debt?
Simply Wall St · 1d ago
Weekly Report: what happened at KURA last week (0707-0711)?
Weekly Report · 1d ago
Weekly Report: what happened at KURA last week (0630-0704)?
Weekly Report · 07/07 09:15
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/03 11:30
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Seeking Alpha · 07/02 04:09
Kura Oncology Partners with Kyowa Kirin for Ziftomenib
TipRanks · 07/01 10:59
Weekly Report: what happened at KURA last week (0623-0627)?
Weekly Report · 06/30 09:16
Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)
TipRanks · 06/26 14:25
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.